Janney Montgomery Scott LLC Sells 1,925 Shares of Axon Enterprise, Inc $AXON

Janney Montgomery Scott LLC cut its position in Axon Enterprise, Inc (NASDAQ:AXON) by 9.0% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 19,575 shares of the biotechnology company’s stock after selling 1,925 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Axon Enterprise were worth $10,974,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AXON. North Dakota State Investment Board grew its holdings in shares of Axon Enterprise by 4.3% during the second quarter. North Dakota State Investment Board now owns 2,248 shares of the biotechnology company’s stock valued at $1,260,000 after buying an additional 92 shares during the last quarter. 71 West Capital Partners increased its position in shares of Axon Enterprise by 9.2% during the second quarter. 71 West Capital Partners now owns 1,394 shares of the biotechnology company’s stock valued at $781,000 after acquiring an additional 117 shares in the last quarter. Checchi Capital Advisers LLC purchased a new position in Axon Enterprise in the 2nd quarter worth approximately $222,000. McAdam LLC purchased a new position in Axon Enterprise in the 2nd quarter worth approximately $214,000. Finally, Transcend Capital Advisors LLC raised its holdings in Axon Enterprise by 6.5% in the 2nd quarter. Transcend Capital Advisors LLC now owns 2,629 shares of the biotechnology company’s stock worth $1,474,000 after acquiring an additional 160 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Northland Securities raised several future earnings estimates. The firm lifted its FY2027 EPS forecast to $6.49 from $5.53 and increased estimates for Q1–Q4 2027, as well as Q3 2026. The revisions suggest stronger anticipated earnings from Axon’s connected-device, software, AI and public-safety technology businesses.
• Positive Sentiment: Axon raised its 2026 revenue-growth outlook to 32%–34%. Management cited strong momentum in connected devices, international demand, counter-drone products and AI-enabled software, supported by approximately $15.1 billion in future contracted bookings. Axon Enterprise Is Up 17.8% After Raising 2026 Revenue Outlook
• Neutral Sentiment: Recent quarterly results exceeded expectations. Second-quarter revenue increased 35.3% year over year to $904.4 million and topped consensus, while adjusted EPS also beat estimates. However, reported net income and diluted EPS declined, highlighting the trade-off between rapid expansion and near-term profitability. The 5 Most Interesting Analyst Questions From Axon’s Q2 Earnings Call
• Negative Sentiment: Northland reduced its FY2026 EPS forecast to $3.12 from $3.26 and cut its Q4 2026 estimate to $1.29 from $1.55. These downgrades indicate some near-term earnings pressure even though longer-term forecasts improved.
• Negative Sentiment: Insider selling added pressure. A report attributed a 6.5% decline to recent insider sales, which can raise concerns about valuation or management’s view of near-term upside. Axon Enterprise Trading Down Following Insider Selling
• Negative Sentiment: Valuation and margins remain risks. With a very high earnings multiple and reported margin contraction, investors may be demanding clearer evidence that revenue growth will translate into sustained profit growth.

Axon Enterprise Stock Performance

AXON opened at $612.83 on Friday. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. The company has a market cap of $49.79 billion, a price-to-earnings ratio of 254.29, a PEG ratio of 12.50 and a beta of 1.39. The company’s 50 day moving average is $526.06 and its 200 day moving average is $474.40. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $794.29.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The business had revenue of $904.39 million during the quarter, compared to analysts’ expectations of $876.42 million. During the same period in the prior year, the company earned $2.12 earnings per share. The firm’s revenue was up 35.3% on a year-over-year basis. On average, equities research analysts predict that Axon Enterprise, Inc will post 2.04 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In related news, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total value of $800,000.00. Following the transaction, the insider directly owned 52,813 shares of the company’s stock, valued at approximately $21,125,200. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of Axon Enterprise stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total value of $753,690.00. Following the transaction, the insider owned 34,024 shares in the company, valued at $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 68,989 shares of company stock worth $36,016,932. Insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Piper Sandler increased their target price on Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Royal Bank Of Canada restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. JPMorgan Chase & Co. upped their price target on Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. UBS Group upped their price target on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Finally, Barclays increased their price objective on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $730.92.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.